177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy

Sarah Clements; Daniel Tempesta; Heather Jacene

doi:10.2967/jnmt.122.264731

Research ArticlePractical Protocol Tip

¹⁷⁷Lu-Vipivotide Tetraxetan (¹⁷⁷Lu-PSMA-617, Pluvicto) Therapy

Sarah Clements, Daniel Tempesta and Heather Jacene

Journal of Nuclear Medicine Technology September 2022, 50 (3) 213-214; DOI: https://doi.org/10.2967/jnmt.122.264731

Sarah Clements

CNMT

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniel Tempesta

CNMT

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heather Jacene

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Tables

View popup
TABLE 1.
Radiopharmaceutical, Dose, Administration Route, and Infusion Duration of ¹⁷⁷Lu-Vipivotide Tetraxetan (1)
Radiopharmaceutical Dose Administration route Infusion duration
¹⁷⁷Lu-vipivotide tetraxetan (Pluvicto, ¹⁷⁷Lu-PSMA-617) 7.4 GBq (200 mCi) Intravenous 1–10 min

PreviousNext

In this issue

Journal of Nuclear Medicine Technology

Vol. 50, Issue 3

September 1, 2022

Table of Contents
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine Technology

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.

Your Personal Message

Citation Tools

¹⁷⁷Lu-Vipivotide Tetraxetan (¹⁷⁷Lu-PSMA-617, Pluvicto) Therapy

Sarah Clements, Daniel Tempesta, Heather Jacene

Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 213-214; DOI: 10.2967/jnmt.122.264731

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

¹⁷⁷Lu-Vipivotide Tetraxetan (¹⁷⁷Lu-PSMA-617, Pluvicto) Therapy

Sarah Clements, Daniel Tempesta, Heather Jacene

Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 213-214; DOI: 10.2967/jnmt.122.264731

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Main menu

User menu

Search

¹⁷⁷Lu-Vipivotide Tetraxetan (¹⁷⁷Lu-PSMA-617, Pluvicto) Therapy

Article Figures & Data

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles